Twist Bioscience Corporation TWST will release earnings results for its fourth quarter, before the opening bell on Monday, Nov. 18.

Analysts expect the South San Francisco, California-based bank to report a quarterly loss at 69 cents per share, versus a year-ago loss of 75 cents per share. Twist Bioscience projects to report revenue of $82.66 million for the recent quarter, compared to $66.95 million a year earlier, according to data from Benzinga Pro.

On Oct. 22, Twist Bioscience entered into royalty purchase agreement with xOMA Royalty for $15 million in cash.

Twist Bioscience shares fell 5.3% to close at $36.89 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

• JP Morgan analyst Tycho Peterson maintained an Underweight rating and raised the price target from $28 to $35 on Aug. 5. This analyst has an accuracy rate of 77%.
• Baird analyst Catherine Ramsey maintained an Outperform rating and raised the price target from $40 to $46 on Aug. 5. This analyst has an accuracy rate of 78%.
• Goldman Sachs analyst Matthew Sykes maintained a Buy rating and increased the price target from $45 to $55 on July 9. This analyst has an accuracy rate of 64%.
• TD Cowen analyst Steven Mah maintained a Buy rating and raised the price target from $55 to $65 on June 13. This analyst has an accuracy rate of 64%.

Considering buying TWST stock? Here’s what analysts think:

Read This Next: